HbA1c变异性与城市多民族1型糖尿病人群糖尿病肾病进展独立相关
在伦敦两家大学医院2004至2018年门诊1型糖尿病且基线eGFR≥45 ml/min per 1.73 m2的多民族队列中,3466人随访中位8.2年,249人(7%)发生肾病进展;三种方法评估的HbA1c变异性均与肾病进展独立相关,非洲加勒比裔风险亦增加。
要点
- 长期个体内HbA1c变异性是1型糖尿病肾病进展的独立危险因素。
- 三种HbA1c变异性评估方法与肾病进展风险均独立相关。
- 非洲加勒比裔1型糖尿病患者肾病进展风险增加,独立于血糖变异性。
核心结论
- 在多民族1型糖尿病队列中,用三种不同方法评估的HbA1c变异性与显著的肾病进展独立相关。
- 需要进一步研究阐明可能解释该结果的机制,并评估HbA1c变异性是否为可改变的危险因素以预防糖尿病肾病进展。
研究设计与样本
- 研究为队列研究,收集伦敦两家大型大学医院2004至2018年门诊就诊者的电子健康记录数据。
- 共纳入3466名1型糖尿病患者,基线eGFR≥45 ml/min per 1.73 m2,且均有6次或以上随访HbA1c测量。
- 肾病进展定义为eGFR较基线下降≥50%且最终eGFR<30 ml/min per 1.73 m2。
- HbA1c变异性用三种方法评估:HbA1c标准差(SD-HbA1c)、访视校正标准差(adj-HbA1c)、变异系数(CV-HbA1c)。
- eGFR采用慢性肾脏病流行病学协作组公式计算,临床和生化结果取自常规诊疗的电子健康记录。
主要发现
- 3466名参与者中50%为女性,78%为白人,13%为非洲加勒比裔,3%为亚裔,6%为混血或自报「其他」。
- 随访中位(IQR)8.2(4.2-11.6)年,249人(7%)出现肾病进展。
- HbA1c变异性越高,肾病进展风险越高,方法1至3的最低与最高变异性四分位比较的HR(95%CI)分别为7.76(4.54, 13.26)、2.62(1.75, 3.94)和5.46(3.40, 8.79)。
- 年龄增加、基线HbA1c、收缩压和尿白蛋白/肌酐比值亦与肾病进展相关(所有P<0.05)。
- 非洲加勒比裔与肾病进展风险增加相关,方法1至3的HR(95%CI)分别为1.47(1.09, 1.98)、1.76(1.32, 2.36)和1.57(1.17, 2.12),且独立于血糖变异性及其他传统危险因素。
关键数值与推荐
- 肾病进展定义为eGFR较基线下降≥50%且最终eGFR<30 ml/min per 1.73 m2。
- HbA1c变异性方法1(SD-HbA1c)最低与最高四分位比较的HR(95%CI)为7.76(4.54, 13.26)。
- HbA1c变异性方法2(adj-HbA1c)最低与最高四分位比较的HR(95%CI)为2.62(1.75, 3.94)。
- HbA1c变异性方法3(CV-HbA1c)最低与最高四分位比较的HR(95%CI)为5.46(3.40, 8.79)。
- 非洲加勒比裔方法1至3的HR(95%CI)分别为1.47(1.09, 1.98)、1.76(1.32, 2.36)和1.57(1.17, 2.12)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以阐明可能解释该结果的机制,并评估HbA1c变异性是否为可改变的危险因素以预防糖尿病肾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The role of HbA1c variability in the progression of diabetic kidney disease is unclear, with most studies to date performed in White populations and limited data on its role in predicting advanced kidney outcomes. Our aim was to evaluate if long-term intra-individual HbA1c variability is a risk factor for kidney disease progression (defined as an eGFR decline of ≥50% from baseline with a final eGFR of <30 ml/min per 1.73 m2) in an ethnically heterogeneous cohort of people with type 1 diabetes with a preserved eGFR ≥45 ml/min per 1.73 m2 at baseline. METHODS: Electronic health record data from people attending outpatient clinics between 2004 and 2018 in two large university hospitals in London were collected. HbA1c variability was assessed using three distinct methods: (1) SD of HbA1c (SD-HbA1c); (2) visit-adjusted SD (adj-HbA1c): SD-HbA1c/√n/(n-1), where n is the number of HbA1c measurements per participant; and (3) CV (CV-HbA1c): SD-HbA1c/mean-HbA1c. All participants had six or more follow-up HbA1c measurements. The eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration equation and clinical/biochemical results from routine care were extracted from electronic health records. RESULTS: In total, 3466 participants (50% female, 78% White, 13% African Caribbean, 3% Asian and 6% of mixed heritage or self-reporting as 'other') were followed for a median (IQR) of 8.2 (4.2-11.6) years. Of this cohort, 249 (7%) showed kidney disease progression. Higher HbA1c variability was independently associated with a higher risk of kidney disease progression, with HRs (95% CIs) of 7.76 (4.54, 13.26), 2.62 (1.75, 3.94) and 5.46 (3.40, 8.79) (lowest vs highest HbA1c variability quartile) for methods 1-3, respectively. Increasing age, baseline HbA1c, systolic BP and urinary albumin/creatinine ratio were also associated with kidney disease progression (p<0.05 for all). African Caribbean ethnicity was associated with an increased risk of kidney disease progression (HR [95% CI] 1.47 [1.09, 1.98], 1.76 [1.32, 2.36] and 1.57 [1.17, 2.12] for methods 1-3, respectively) and this effect was independent of glycaemic variability and other traditional risk factors. CONCLUSIONS/INTERPRETATION: We observed an independent association between HbA1c variability, evaluated using three distinct methods, and significant kidney disease progression in a multi-ethnic type 1 diabetes cohort. Further studies are needed to elucidate the mechanisms that may explain our results and evaluate if HbA1c variability is a modifiable risk factor for preventing diabetic kidney disease progression.
引用
- Muthukumar A, Badawy L, Mangelis A, et al. HbA1c variability is independently associated with progression of diabetic kidney disease in an urban multi-ethnic cohort of people with type 1 diabetes. Diabetologia. 2024. PMID: 38902524. doi:10.1007/s00125-024-06197-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。